| (Values in U.S. Thousands) | Dec, 2010 | Dec, 2009 | Dec, 2008 | Dec, 2007 | Dec, 2006 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -10,160 | -13,460 | 0 | -6,810 | -7,040 |
| Net Income Growth | +24.52% | unch | unch | +3.27% | -31.84% |
Pimco Energy and Tactical Opportunities Fund (NRGX)
Pimco Energy and Tactical Opportunities Fund (NRGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Neurologix, Inc. is a Delaware Corporation. It is a development stage company that is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, using gene transfer and other innovative therapies. These treatments are designed as alternatives to conventional surgical and pharmacological treatments. The Company's development efforts are currently focused on gene transfer for treating Parkinson's disease. Its core technology, which it refers to as 'NLX,' is in the clinical development stages and was tested in a Phase 1 and Phase 2 clinical trials to treat Parkinson's disease. Although the Company's operations and resources will be mainly concentrated on its Parkinson's disease therapy, the Company intends to continue to develop therapies to treat other neurodegenerative and metabolic disorders, including therapies relating to epilepsy and Huntington's disease. It faces intense competition from pharmaceutical companies, biotechnology companies, universities, governmental entities and other healthcare providers developing alternative treatments for Parkinson's disease, Huntington's disease and epilepsy.